Fred Aslan - 05 Mar 2025 Form 4 Insider Report for Artiva Biotherapeutics, Inc. (ARTV)

Reporting relationship: President and CEO, Director
Issuer ticker: ARTV
Reported as of: 05 Mar 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Mar 2025, 16:35:00 UTC
Prior SEC filing: 18 Jul 2024
Next SEC filing: 18 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Neha Krishnamohan, Attorney-in-Fact

Filing notes and source

Key filing fact

Fred Aslan filed Form 4 for Artiva Biotherapeutics, Inc. (ARTV) on 07 Mar 2025.

Key facts

This page summarizes Fred Aslan's Form 4 filing for Artiva Biotherapeutics, Inc. (ARTV).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 07 Mar 2025, 16:35.

Change

Previous filing in this sequence was filed on 18 Jul 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ARTV transaction

Common Stock

Award

Transaction value: $0
Shares: +200,000
Change %: +92%
Price: $0.000000
Shares after: 416,665
Date: 05 Mar 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.

Footnote F2

Reflects reduction in the number of shares subject to the RSU granted on July 22, 2024 from 228,905 shares to 216,665 shares. The equity award was originally calculated based on the maximum offering size of the Company's initial public offering (IPO) and such award was subsequently adjusted following the partial exercise of the underwriters option to purchase additional shares in connection with the IPO.